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LYSOZYME is  an  ubiquitous  enzyme  found  in  most
biological secretions and leukocytes. This study was
aimed  at  investigating  its  interaction  with  other
inflammatory mediators on mucosa surfaces, partic-
ularly  the  complement  system.  Lysozyme  has  been
shown in our present study, to inhibit the haemolytic
activity  of  serum  complement  in  a  dose-dependent
fashion,  when  tested  within  the  levels  present  in
normal and inflamed breast-milk samples, and other
mucosal  secretions.  This  represents  a  new  anti-
inflammatory action of  lysozyme in relation  to the
serum  complement,  and  the  exact  mode  of  the
interaction need further studies.
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Introduction
Lysozyme is an  acid- and heat-stable enzyme that  is
abundant  in  the  breast-milk  and  in  most  other
mucosal body-fluids.
1 Lysozyme catalyses the hydroly-
sis of b (–1,4–) linkage between N-acetylglucosamine
and  N-acetylmuramic acid  in the bacterial cell wall.
The  enzyme  lyses  mostly  Gram-positive  and  a  few
Gram-negative bacteria or induces their aggregation.
2
In addition, it possesses prominent anti-inflammatory
properties.
Lysozyme has been shown to inhibit chemotaxis of
activated  leukocytes.  Other  anti-inflammatory  func-
tions  of  lysozyme  include  inhibition  of  mitogen-
induced  lymphoblastogenesis  and  autologus  mixed
lymphocyte  reaction  (at  concentrations  ranging
between 1 and 10 m g/ml).
3
Its interaction  with  the complement (Cp) system
has so far been found to be indirect, by an inhibition
of PMN response towards complement-derived chem-
otaxins. Our present studies have shown that it is also
capable of directly modulating the entire activation of
Cp reaction  cascade. The  exact  mechanism for this
inhibition  is  however,  yet  to  be  fully  examined.
Lysozyme, some milk proteins, such as alpha lactalbu-
min,  and  low-molecular-weight  ligands,  such  as  cit-
rates and phosphates, are known to have high affinity
binding sites for calcium,
4 and may therefore act as
inhibitors of complement indirectly, by chelating the
divalent ions required for complement activation. The
inhibitory effect of lysozyme might also be related to
its  ability  to  degrade  certain  glycoprotein  compo-
nents of native Cp factors.
The serum Cp system consist of at least 19 proteins,
mostly in pre-activated enzymatic forms, activated in a
multi-step cascade reaction via either the classical or
alternative  pathways. The  classical  pathway  is  acti-
vated mainly by antigen–antibody complexes (IgG or
IgM mostly) starting with Clq, Clr, Cls, C4 and C2, and
eventually leading to the activation of C3 by cleavage
into  C3a  and  C3b.  The  alternative  pathway  (APC)
utilizes active sites (such as are present on zymosan,
yeast,  cobra  venom,  most  Gram-negative  bacteria,
sheep erythrocytes and human cells deficient in the
expression of membrane regulatory molecules) in the
presence  of  properdin,  serum  factors  B  and  D,  to
activate C3. This step unifies the two pathways and
proceeds  uniformly  thereafter  to  the  formation  of
(C5b-9) membrane attack complexes (MAC), capable
of inserting into biological membranes and producing
cell  lysis  and  death.  APC  activating  surfaces  are
characterized  by  possession  of  structures  which
restrict  access  to  inhibitory  factor  H  to  deposited
C3b, thereby amplifying the formation of further C3b
in the presence of factor B.
Materials and methods
Buffers
Gelatin veronal buffered saline (GVB
2+) and sucrose
gelatin  veronal-buffered  saline  (SGVB
2+)  with  Ca
2+
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2+ were  prepared  as  described  by  Mayer.
GVB
2– buffer  containing  10 mM  ethylene  diacetyl
ethylamine (EDTA) was used as the stopping solution.
Sucrose-GVB
2+ was  utilized  for  the  serum  comple-
ment  assay  in  place  of  GVB
2+ buffer,  with  ionic
strength of 0.065 and 0.149 respectively.
Purified human lysozyme
Purified lysozyme crystals was  obtained  from  Serva
Feinbiochemica-Heidelberg,  Germany.  It  was  dis-
solved in  SGVB
2+ and  added to  serum complement
assays  in  final  concentrations  ranging  from  50  to
1500 m g/ml.
Sensitized sheep red blood cells
Sheep red blood cells (SRBC) (ORAW 30/31) obtained
from Behringwerke, Marburg, Germany were washed
twice in GVB
2+ buffer and resuspended in the same
buffer.  The  SRBC  concentration  was  standardized
sphectrometrically  by  adding  100 m l  of  the  SRBC
suspension  to  1.9 ml  water  and  reading  the  absor-
bance  at  541nm  (A541)  with  a  spectrophotometer
(Stasar III Gilford Instrument Laboratories, Inc., Ober-
lin,  Ohio). GVB
2+ was added to the SRBC until  the
A541 was 0.468, corresponding to an approximate cell
suspension of 1 3 10
9/ml.
A  sensitized  cell  suspension  was  prepared  by  a
dropwise addition of an equal volume of anti-Forsman
haemolysin  (diluted  1:300  in  GVB
2+ containing
20 mM  EDTA)  to  the  previously  prepared  SRBC
suspension.  The  cells  were  incubated  at  37°C  for
30 min and at 0–2°C for a further 30 min. The cells
were then washed once in SGVB
2+ and resuspended
in this buffer. A final suspension of 5 3 10
8 cells/ml,
obtained by an equal addition of an equal volume of
buffer, was employed in the test assays.
Normal human serum haemolytic assay
Serum samples were obtained from 10 healthy blood
donors. A micro-modification of the standard haemo-
lytic  assay  was  used  for  the  assessment  of  serum
complement  activity. A  1:20  dilution  of  serum  was
prepared, different  volumes (12.5–100 m l) of which
was pipetted into the assay tubes, as well as 40 m l of
sensitized SRBC, to obtain a total reaction volume of
375 m l, SGVB
2+ buffer was used for the serum assay,
incubating  the  mixture  for  60 min  at  37°C,  with
occasional  mixing.  After  pelleting  the  remaining
intact cells, 200 m l of each supernatant was pipetted
into a 96-well flat-bottomed microtitre plates (Greiner
Labortechnik,  Frickenhausen,  Germany)  and  the
amount of the released haemoglobin  recorded by  a
plate  sphectrophotometer  (MR  700  microplate
reader,  Dynatech  Instruments,  Inc.,  Torrance,  Cal-
ifornia) at a test wavelength of 410 against a reference
wavelength of 630. The degree of lysis produced was
obtained from the equation
Y =
Test OD – Spontaneous lysis OD
– Serum blank OD
H2O lysis OD
– Spontaneous lysis OD
3 100
Assays of serum complement inhibition by
lysozyme
Using the modified CH50 assay as described above, a
constant volume of serum, containing approxmately
one CH50 unit, and SRBC, were pipetted into assay
tubes. Lysozyme was added before incubation of the
the reaction mixtures, at final concentrations ranging
from 50 to 1500m g/ml.
Result
Lysozyme was added to the serum as a source of Cp in
CH50 whole Cp assays. Concentrations ranging from
50  to  1500 m g/ml  were  added,  corresponding  to
expected  physiological  and  pathological  levels  of
lysozyme in the colostrum, mature or inflamed breast-
milk,  as  well  as  other  normal  and  inflamed  body
fluids.  Lysozyme  was  found  to  inhibit  the  whole
serum  complement  activity,  mainly  the  classical
pathway tested by CH50 assays, in a dose-dependent
fashion (Fig. 1). At low concentrations corresponding
to physiological levels, the inhibitory effect of lyso-
zyme was relatively minimal. The inhibition thereafter
rises sharply with increasing concentrations, within
pathological ranges.
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FIG.  1.  Inhibitory  effect  of  human  lysozyme  on  serum
complement activation. d , % inhibition of serum comple-
ment activation (average ± SEM, n = 2).Discussion
Despite widespread notions about insignificant roles
of the inflammatory processes of the Cp system in
mucosal secretions,
5 the Cp system might still repre-
sent  a  major  anti-microbial  armoury  on  mucosal
surfaces. A recent series of studies have demonstrated
in vitro Cp-mediated bacteriolytic activities against a
serum-sensitive Escharichia coli, Staphylococcus aur-
eus and S. epidermidis in human breast-milk (HBM).
Furthermore, non-immune mechanisms of Cp activa-
tion  have been  demonstrated in  the mucosal secre-
tions of the lacrimal gland, suggesting that the well-
known  inhibition  of  classical  pathways  of  Cp
activation at these mucosal sites by secretory compo-
nents such as lactoferrin, could still be circumvented.
In  the HBM, apart  from the Cp and free fatty  acids
(FFA), most of the other anti-microbial components of
HBM are bacteriostatic. Since bactericidal FFA are also
present in the artificial formula feeds, and they do not
seem to contribute to the protection of the formula-
fed  infants,  the  Cp  system  should  therefore  be
regarded  as  a  potentially  significant  source  of  con-
tribution  to  the  observed  resistance  of  breast-fed
infants against infection.
Lysozyme was found  to inhibit  the classical path-
way of serum complement activity in a dose-depend-
ent  fashion,  particularly  within  the  pathological
ranges. The levels of both mucosal lysozyme and Cp
components are known to increase during periods of
infection. This  would  suggest  that  the  mucosal  Cp
might be actively involved in bacteriolysis, opsoniza-
tion and modulation of immune responses at mucosal
surfaces, in the absence of full-blown inflammation,
to  protect  the  body  against  the  constant  threat  of
foreign  invaders. The presence of anti-inflammatory
secretory components would  then  serve to protect
the  tissues  against  secondary  damage  during  acute
overwhelming infections, where excessive inflamma-
tory reactions of the Cp would be undesirable.
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